Faced with historic launch, Biogen to ship Alzheimer's drug in 2 weeks as nearly 1K treatment sites stand ready to go

With an FDA nod in hand for Alzheimer's disease drug Aduhelm, Biogen faces what analysts have chalked up to be one of the biggest drug launches in biopharma history. With those high expectations set, Biogen's top brass say they're ready to infiltrate the untapped market—starting with deliveries to nearly 1,000 infusion centers across the U.S.